Poor 1st-year adherence to anti-osteoporotic therapy increases the risk of mortality in patients with magnetic resonance imaging-proven acute osteoporotic vertebral fractures
- PMID: 28490865
- PMCID: PMC5414717
- DOI: 10.2147/PPA.S131564
Poor 1st-year adherence to anti-osteoporotic therapy increases the risk of mortality in patients with magnetic resonance imaging-proven acute osteoporotic vertebral fractures
Abstract
Aim: Anti-osteoporotic therapy requires years of proper compliance to reduce the risk of fractures. This study investigated the effects of 1st-year adherence to anti-osteoporotic treatment on the risk of mortality in patients with magnetic resonance imaging-proven acute osteoporotic vertebral fractures after vertebroplasty.
Patients and methods: This retrospective study included 294 patients (252 females; mean age, 73.93±7.18 years) with osteoporosis and acute vertebral fractures treated with vertebroplasty between January 2001 and December 2007. Sex, age, body mass index, comorbidities, previous hip fracture, number of vertebral fractures, 5-year re-fracture rate, and use of anti-osteoporotic therapy were recorded for each patient. Adherence was determined according to compliance and persistence for 1 year. Compliance was calculated as the medication possession ratio (MPR), and persistence as the time from treatment initiation to discontinuation. Poor adherence was defined as either non-compliance or non-persistence.
Results: The MPR of the patients at 1 year was 55.1%, with a persistence rate of 69.4% and a poor adherence rate of 62.6%. Cox regression analysis revealed that poor adherence to medications was associated with a significantly higher risk of mortality after adjustment for potential confounders (hazard ratio [HR]: 1.75; 95% CI: 1.13-2.71). Poor adherence to medications was significantly associated with an increase in the rate of infection (HR: 4.56; 95% CI: 1.12-18.52), which was the most common cause of death.
Conclusion: Poor adherence to anti-osteoporotic therapy significantly increases the risk of morality, possibly due to an increased risk of infection. Efforts should be made to improve adherence.
Keywords: adherence; mortality; osteoporosis; vertebral fracture.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Figures
Similar articles
-
Can anti-osteoporotic therapy reduce adjacent fracture in magnetic resonance imaging-proven acute osteoporotic vertebral fractures?BMC Musculoskelet Disord. 2016 Apr 6;17:151. doi: 10.1186/s12891-016-1003-1. BMC Musculoskelet Disord. 2016. PMID: 27052323 Free PMC article.
-
Medical specialty-related adherence to anti-osteoporotic regimens in fragility hip fracture patients.J Bone Miner Metab. 2015 Sep;33(5):577-83. doi: 10.1007/s00774-014-0621-7. Epub 2014 Sep 21. J Bone Miner Metab. 2015. PMID: 25240801
-
Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.Osteoporos Int. 2017 Mar;28(3):799-809. doi: 10.1007/s00198-016-3888-9. Epub 2016 Dec 27. Osteoporos Int. 2017. PMID: 28028555 Free PMC article.
-
Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review.Clin Ther. 2019 Aug;41(8):1576-1588. doi: 10.1016/j.clinthera.2019.05.001. Clin Ther. 2019. PMID: 31151814
-
Mortality Outcomes of Vertebral Augmentation (Vertebroplasty and/or Balloon Kyphoplasty) for Osteoporotic Vertebral Compression Fractures: A Systematic Review and Meta-Analysis.Radiology. 2020 Apr;295(1):96-103. doi: 10.1148/radiol.2020191294. Epub 2020 Feb 18. Radiology. 2020. PMID: 32068503
Cited by
-
Insufficient persistence to pharmacotherapy in Japanese patients with osteoporosis: an analysis of the National Database of Health Insurance Claims and Specific Health Checkups in Japan.Arch Osteoporos. 2021 Sep 13;16(1):131. doi: 10.1007/s11657-021-00993-8. Arch Osteoporos. 2021. PMID: 34515872
-
Effects of Frailty Syndrome on Osteoporosis, Focusing on the Mediating Effect of Muscle Strength and Balance in Community-Dwelling Older Adults (≥60 years) in Iran: Results From the Amirkola Health and Aging Project Cohort Study.Geriatr Orthop Surg Rehabil. 2024 Jul 25;15:21514593241264647. doi: 10.1177/21514593241264647. eCollection 2024. Geriatr Orthop Surg Rehabil. 2024. PMID: 39070931 Free PMC article.
-
Medication holidays in osteoporosis: evidence-based recommendations from the Italian guidelines on 'Diagnosis, risk stratification, and continuity of care of fragility fractures' based on a systematic literature review.Ther Adv Musculoskelet Dis. 2023 Jun 19;15:1759720X231177110. doi: 10.1177/1759720X231177110. eCollection 2023. Ther Adv Musculoskelet Dis. 2023. PMID: 37359175 Free PMC article. Review.
-
Vertebral augmentation reduces the 12-month mortality and morbidity in patients with osteoporotic vertebral compression fractures.Eur Radiol. 2021 Nov;31(11):8246-8255. doi: 10.1007/s00330-021-07985-9. Epub 2021 Apr 26. Eur Radiol. 2021. PMID: 33899142
-
Incidence of different types of subsequent fractures and related mortality in Taiwan.Arch Osteoporos. 2022 Apr 1;17(1):55. doi: 10.1007/s11657-022-01098-6. Arch Osteoporos. 2022. PMID: 35364728
References
-
- Gordis L. Symposium in honor of Abraham M. Lilienfeld. Chronic disease epidemiology at the threshold of a new decade. Am J Epidemiol. 1980;112(2):169–177. - PubMed
-
- Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab. 2011;96(4):1006–1014. - PubMed
-
- Gordis L. Assuring the quality of questionnaire data in epidemiologic research. Am J Epidemiol. 1979;109(1):21–24. - PubMed
-
- Haynes RB, Sackett DL, Taylor DW. How to detect and manage low patient compliance in chronic illness. Geriatrics. 1980;35(1):91–93. 96–97. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources